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Ischaemic Stroke in the Time of Coronavirus Disease 2019  
 
Introduction 
Each year, between 1.1 and 1.5 million Europeans have a stroke1. Two to three out of 10 
patients die as a consequence of it and about one third remains functionally dependent2. As 
we know, the likelihood of a favourable outcome in this disease relies heavily on patients 
presenting promptly after symptoms onset and on hospitals providing immediate access to 
optimized stroke care3,4.   
Since the first reported case in early December 2019, severe acute respiratory coronavirus 2 
(SARS-CoV-2) infection, known as Coronavirus Disease 2019 (COVID-19), has become 
pandemic so rapidly that healthcare systems are overwhelmed5-7.  In Spain, by April 19th, 
195,944 cases and 20,453 deaths have been confirmed8. With our health system on the 
brink of collapse, there is a risk that the remaining “non-COVID-19" pathologies lag behind 
and, unfortunately, it seems stroke is not an exception. 
Stroke assistance is facing changes and new challenges. In a survey, among 426 stroke 
care providers from 55 countries, only one in five reported that stroke patients are currently 
receiving the standard acute and post-acute care9. Furthermore, it seems that fewer people 
are coming to emergency departments or are doing it too late. However, data quantifying this 
is lacking. 
We aim to analyze the impact of COVID-19 epidemic outbreak on hospital stroke admissions 
and patients baseline characteristics in our region. Aragón represents one of the 17 first-
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number of confirmed SARS-CoV-2 cases and deaths. It has 1,319,291 inhabitants and 
around 2000 cases of stroke admissions per year. According to our regional Health System 
(Servicio Aragonés de Salud), public hospitals are the only ones where reperfusion therapies 
for ischaemic stroke are available. 
Methods 
We reviewed the data of every patient admitted to any hospital of Servicio Aragonés de 
Salud (SALUD) with the diagnosis of ischaemic stroke between December 30th 2019 and 
April 19th 2020. Demographic and clinical data were recorded including age, sex, modified 
Rankin Scale score (mRS) prior to qualifying stroke, patient location, time of onset, Code 
Stroke activation, National Institutes of Health Stroke Scale score (NIHSS), Alberta Stroke 
Program Early CT Score (ASPECTS), intravenous thrombolysis (IVT) and/or endovascular 
therapy (EVT), onset-to-door time (ODT), door-to-needle time (DNT), door-to-puncture time 
(DTP) and COVID-19 diagnostic test results. The number of stroke patients and confirmed 
COVID-19 cases were quantified per week (depicted according to ISO 8601:2019 
standards). Weekly national policies carried out on the COVID-19 pandemic were taken into 
account.   
We used descriptive statistics to compare the incidence of stroke admissions before and 
after the setting of the state of emergency in our country (March 14th 2020) expressed in 
strokes per week and the differences between the baseline characteristics and 
demographics of patients attended in those periods. Quantitative variables were reported as 
medians with interquartile ranges (IQR) and tested for differences with the Mann-Whitney U 
and Kruskal-Wallis tests. Chi-square tests were used to test for differences in dichotomous 
variables.  
Ethical approval for this study was obtained from the regional Research Ethics Committee, 
“Comité de Ética de la Investigación de la Comunidad Autónoma de Aragón” (CEICA). 
 
Results 
In total, 354 patients with ischaemic stroke (male 185, 52.3%); median of age 79, (IQR 68-
86), were admitted to a hospital at SALUD between December 30th 2019 and April 19th 
2020. There was a weekly average of 27.5 cases before the setting of the state of 
emergency against 12 afterwards (p<0,001). This drop in stroke cases occurred 
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decrease in confirmed cases of COVID-19 (Figure 1). This also happened in the number of 
patients who received reperfusion therapies, IVT and/or EVT, per week (8.5 vs 4, p = 0.011). 
There were no differences in the proportion of IVT (21.1% vs 21.5%, p = 0,935) or EVT 
(12.4% vs 15.2%, p = 0,510) of the total amount of ischaemic stroke of each period, nor in 
the other demographic or clinical characteristics except for median ODT (102 vs 183 
minutes, p = 0.015) (Table 1). Only 28 stroke patients were tested for COVID-19 according 
to clinical suspicion, six of them were positive (21.4%). 
Discussion 
Aragón is the fourth largest administrative division in Spain and the 11th most populated. 
Among its major demographic characteristics are the dispersion and elderly population 
(285,599 people older than 65 years, which represents 21,65%). The population is very 
unevenly distributed, with the main province gathering 964,693 inhabitants (Zaragoza), but 
an average population-density for the rest of the territory fewer than 20 inhabitants/km2. 
SALUD is the entity responsible for health care in the region, assisting 97% of its citizens. 
The entire territory is covered by 8 district health boards, each one with a referral hospital. 
Three of the districts correspond to the city of Zaragoza, while the rest provide care for less 
inhabited areas. There is one tertiary referral hospital for stroke EVT in the whole region, and 
all the other hospitals can offer IVT. The whole SALUD uses the same electronic medical 
record and  has common stroke entry/discharge reports, allowing exploitation of stroke 
hospital data from all over Aragón in real-time. 
On March 14th 2020, the Government of Spain implemented extraordinary measures to 
control viral transmission, restricting free mobility over the entire country. This was reinforced 
from March 31st to April 11th, being essential workers the only ones allowed to leave their 
homes. Until now, the state of emergency is still on. We believe the significant reduction in 
current stroke admissions might be related to fewer people going to the Emergency 
Department due to fear of being infected and in response to the measures previously 
described. This might make sense in minor non-disabling strokes. However, it is hard to 
assume that a severely disabling stroke, such as those secondary to large-vessel occlusion, 
did not come to the hospital, even if it was late for reperfusion treatments. Having said that, 
although there was a decrease in the number of patients who received reperfusion therapies 
per week, we did not find changes in the proportion of IVT and EVT patients in our region, if 
we compared it with the total amount of ischaemic strokes for each period. There was also a 
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with strokes of more than 24 hours of evolution or those with unknown time of symptom 
onset. 
It seems unlikely that COVID-19 is directly related to the decrease in the influx of ischaemic 
stroke patients to our emergency departments. Furthermore, possible mechanisms by which 
SARS-CoV-2 may increase the risk of stroke have been described: angiotensin-converting 
enzyme 2 (ACE2) receptor may act as an entry for SARS-CoV-2 causing neurological 
complications such stroke through direct and indirect mechanisms10. The high level of D-
dimer, low platelet count and production of antiphospholipid antibodies predispose to a 
hypercoagulative state11-13. Besides, SARS-CoV-2 is reported to cause cytokine storm 
syndromes, which could contribute to stroke. Hypoxia in the central nervous system derived 
from alveolar gas exchange disorder, cardioembolism due to virus-related cardiac injury, or 
direct virus nervous system invasion are other proposed mechanisms. Nevertheless, these 
associations remain to be determined14. 
Considering frailty and strict social isolation, older patients could be at higher risk of dying at 
home from this or other diseases if they do not seek emergency services. In fact, it is the 
age group with higher mortality from COVID-19 and also the one with more ischaemic stroke 
rates. However, this would have increased the proportion of strokes in young adults, which 
did not happen. Another hypothesis is that some stroke patients could be in a different in-
patient area and would have not been transferred to the Neurology ward. Considering the 
actual hospital organization derived from COVID-19, patients hospitalized with other 
diseases could either be in isolation units where stroke might not be the major issue or not 
being paid enough attention to make the diagnosis, which would be a serious 
inconvenience. As a result, some patients might not be receiving the necessary stroke 
standard of care. 
On the other hand, it seems that around 29% of the global burden of stroke may be 
attributed to air pollution15. The measures adopted to control viral transmission in Spain have 
led to a drastic and general reduction in urban transportation, industrial activity and other 
sources of environmental pollution. There has been a 77% decrease in road traffic in main 
Spanish cities, with a maximum near 90% on weekends. In Zaragoza, this reduction has 
contributed to a 45% decrease in the NO2 levels registered in the city16. It would be tempting 
to assume that isolation might have contributed to better control of some modifiable stroke 
risk factors, making it plausible that the decrease in stroke admissions in this period might 
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Questions might arise whether the seasonal pattern of stroke occurrence may play a role in 
our results, but evidence about it is conflicting. Some studies report that ischaemic stroke 
events are significantly higher during spring and autumn than in summer17,18 and, in our case, 
the drop in stroke admissions has occurred during the beginning of spring. However, another 
study stated that there was a fairly even distribution of ischaemic stroke over all four 
seasons19 and a recent meta-analysis showed very little seasonal variation20. 
The higher ODT observed in our sample could be secondary to the collapse of the 
emergency services, focused on the transfers of COVID-19 patients. On the other hand, we 
think that fear could also delay stroke activation by patients or their families. 
To the best of our knowledge, this is the first study that quantifies the impact of COVID-19 
outbreak in stroke hospital admissions in an entire region. However, some limitations should 
be noted. First, the way records were obtained from the SALUD database limits stroke 
events to the ones which cerebrovascular disease was among the main diagnosis during 
hospitalization. This did not allow us to thoroughly assess the characteristics of the whole 
COVID-19 population suffering from ischaemic stroke, but other series analyzing these 
aspects found that the incidence of acute ischaemic stroke in this population is no more than 
5%21. Second, the time frame to analyze how SARS-CoV-2 infection and policies affect 
stroke care is short, but due to the urge for some advice to other countries which are in a 
previous phase of the epidemic, we considered this registered month significant enough to 
obtain interesting data that could help stroke centres. 
Conclusions 
This observational study offers the perspective of a whole region in one of the countries 
more heavily stricken by the SARS-CoV-2 epidemic. It shows that the decrease of stroke 
events, since the beginning of COVID-19 outbreak, happened globally and without any 
specific patient distribution. This forces us to stay alert and make a thorough scout of 
ischaemic strokes. It might be useful to remind the general population and other health 
services that Code Stroke has not suffered from new policies and diversion of resources and 
to highlight the importance of alert activation in order to provide potential patients with the 
care that they deserve. 
Data Availability Statement 
The data that support the findings of this study are available from the corresponding author 
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pre-CoV 
(n = 275) 
p-CoV 
(n = 79) p 
Age, median (IQR) 80 (68.0 - 86.0) 78 (67.0 - 85.0) 0.298 
> 80 years, n (%) 130 (47.3) 32 (40.5) 0.287 
Male, n (%) 143 (52.0) 42 (53.2) 0.855 
In-hospital stroke, n (%) 15 (5.5) 5 (6.3) 0.783 
Strokes per week, median (IQR) 27.5 (22.5 - 33.5) 12 (10.8-16) <0.001 
TP per week, median (IQR)¥ 8.5 (6.3-9.3) 4 (2.5-5.3) 0.011 
IVT, n (%) 58 (21.1) 17 (21.5) 0.935 
EVT, n (%) 34 (12.4) 12 (15.2) 0.510 
>24h from SO, n (%) 59 (21.5) 10 (12.7) 0.082 
Unknown-onset stroke, n (%) 129 (46.9) 35 (44.3) 0.682 
ODT in minutes, median (IQR)^ 102 (65.3 - 196.8) 183 (80.0 - 532.0) 0.015 
mRS >2, n (%) 39 (14.2) 15 (19.0) 0.295 
Patients from retirement homes, n (%) 18 (6.5) 4 (5.1) 0.794 
Brought in ambulance 90 (32.7) 32 (40.5) 0.200 
ASPECTS, median (IQR)* 10 (9 - 10) 10 (9 - 10) 0.309 
ASPECTS <6, n (%)* 9 (4.0) 4 (5.9) 0.508 
NIHSS, median (IQR) 5 (2 - 11) 6 (3 - 12) 0.156 
NIHSS <5, n (%) 143 (52.0) 38 (48.1) 0.541 
NIHSS >15, n (%) 39 (14.2) 13 (16.5) 0.615 
DNT in minutes, median (IQR) 50 (35.0 - 70.3) 64 (38.5 - 89.0) 0.112 
DPT in minutes, median (IQR) 59.5 (37.3 - 108.5) 68 (41.8 - 126.8) 0.388 
Abbreviations: intravenous treatment (IVT), endovascular treatment (EVT), treated patients 
(TP), symptoms onset (SO), onset-to-door time (ODT), door-to-needle time (DNT), door-to-

















Clinical characteristics of stroke admissions in Aragón before (pre-CoV) and after (p-CoV) the setting of the 
state of emergency in Spain 
¥ Treated patients as the ones who recieved IVT and/or EVT 
^Out-of-hospital patients with less than 24 hours from symptoms onset 
*Only patients with anterior circulation strokes 
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